{"slug":"psychiatric-therapeutics","topic":"psychiatric-therapeutics","title":"Novel Psychiatric Therapeutics: State of the Field (October 2026)","summary":"This dossier maps the evidence on psychedelic-assisted therapy, rapid-acting antidepressants, muscarinic antipsychotics, neurosteroids and accelerated neuromodulation as of October 2026. The central takeaway is that small psilocybin trials report large and sometimes durable effects, but larger placebo-controlled and longer studies are still needed to separate drug effects from expectancy and setting. Efficacy results for several registered programs could not be verified from the candidate set and are left out.","version":1,"published_at":"2026-10-30","updated_at":"2026-10-30","stats":{"words":4182,"citations":44,"claims":28,"timeline":19,"benchmarks":9,"open_problems":8,"key_papers":15,"glossary":18},"verification":{"status":"verified","method":"automated figure and citation-relevance triage against cited abstracts, plus targeted AI review with web checks of flagged statements; automated citation resolution","claims_checked":19,"issues_fixed":6,"verified_at":"2026-10-30"},"ai_assisted":true,"price":{"usd":"0.20","protocol":"x402","network":"eip155:84532","asset":"USDC"},"url":"https://space-kitty.com/dossiers/psychiatric-therapeutics","preview_url":"https://space-kitty.com/api/v1/dossiers/psychiatric-therapeutics/preview","purchase_url":"https://space-kitty.com/api/v1/dossiers/psychiatric-therapeutics","toc":[{"level":2,"text":"Executive summary","anchor":"executive-summary"},{"level":2,"text":"Background and core concepts","anchor":"background-and-core-concepts"},{"level":2,"text":"Timeline of key milestones","anchor":"timeline-of-key-milestones"},{"level":2,"text":"State of the art","anchor":"state-of-the-art"},{"level":3,"text":"Psilocybin and other classic psychedelics","anchor":"psilocybin-and-other-classic-psychedelics"},{"level":3,"text":"Rapid-acting antidepressants: ketamine and esketamine","anchor":"rapid-acting-antidepressants-ketamine-and-esketamine"},{"level":3,"text":"Muscarinic antipsychotics: xanomeline-trospium (KarXT)","anchor":"muscarinic-antipsychotics-xanomeline-trospium-karxt"},{"level":3,"text":"Neurosteroids","anchor":"neurosteroids"},{"level":3,"text":"Accelerated neuromodulation","anchor":"accelerated-neuromodulation"},{"level":3,"text":"Quantitative benchmarks","anchor":"quantitative-benchmarks"},{"level":2,"text":"Open problems and active debates","anchor":"open-problems-and-active-debates"},{"level":2,"text":"Major programs and players","anchor":"major-programs-and-players"},{"level":2,"text":"Outlook: what to watch","anchor":"outlook-what-to-watch"},{"level":2,"text":"Key papers","anchor":"key-papers"},{"level":2,"text":"Glossary","anchor":"glossary"}],"sample_claims":["In a 51-patient randomized, double-blind crossover trial in cancer-related distress, high-dose psilocybin produced large decreases in depressed mood and anxiety compared with a very low dose, and about 80% of participants still showed clinically significant decreases at six months.","In a waitlist-controlled trial of 27 randomized adults with major depressive disorder, two psilocybin sessions with psychological support produced a GRID-HAMD effect of Cohen d = 2.5 (95% CI 1.4 to 3.5) at week 5 against the delayed-treatment group."],"includes":["markdown","claims","timeline","benchmarks","open_problems","key_papers","glossary","bibliography"],"citation_count":44,"how_to_buy":"GET https://space-kitty.com/api/v1/dossiers/psychiatric-therapeutics with an x402 client ($0.20, USDC on Base Sepolia (testnet))."}